{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:48Z","timestamp":1791876948024,"version":"4.3.4"},"reference-count":26,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The prognostic impact of monocytic differentiation in patients with acute myeloid leukemia (AML) receiving venetoclax (Ven) and azacitidine (Aza) remains unclear. In a prospective cohort of 86 newly diagnosed patients with AML treated with Ven-Aza, we used multiparametric flow cytometry (MFC) to define monoblasts as AML blasts coexpressing \u22652 monocytic markers (CD4, CD36, and CD64) per European LeukemiaNet (ELN) guidelines. Patients with higher monoblasts\/CD45+ proportions had lower complete response rates (odds ratio, 0.24; P = .005) and significantly shorter overall survival (OS; 4.0 vs 14.9 months; P = .003). A \u226510% monoblasts\/CD45+ threshold, identified via maximally selected rank statistics, stratified patients into monoblasthigh (\u226510%) and monoblastlow (&amp;lt;10%) groups. MFC reclassified 20% of French-American-British (FAB) non-M4\/5 and 15% of FAB M4\/5 cases into monoblasthigh and monoblastlow groups, respectively. Multivariable analysis confirmed monoblasthigh status as an independent adverse prognostic factor for OS (hazard ratio [HR], 1.95; P = .023), with a particularly strong impact in ELN 2024 favorable-risk patients (HR, 2.81; P = .024). Our findings highlight monocytic differentiation, assessed via MFC, as a key predictor of Ven-Aza resistance and poor survival, independent of genetic classification. Given its availability in routine diagnostics, MFC-based monocytic assessment could improve AML risk stratification and treatment decisions in patients eligible for less intensive therapies. This trial was registered at www.clinicaltrials.gov as #NCT05326919.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015734","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T16:13:18Z","timestamp":1744992798000},"page":"3556-3565","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic significance of monocytic-like phenotype in patients with AML treated with venetoclax and azacytidine"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-4470","authenticated-orcid":false,"given":"Lin-Pierre","family":"Zhao","sequence":"first","affiliation":[{"name":"1Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1342, Institut de Recherche Saint-Louis, Paris, France"},{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"3Service H\u00e9matologie Seniors, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9825-2254","authenticated-orcid":false,"given":"Typhaine","family":"Dumas-Rivero","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1342, Institut de Recherche Saint-Louis, Paris, France"},{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"4Laboratoire d\u2019H\u00e9matologie, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Barette","sequence":"additional","affiliation":[{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"3Service H\u00e9matologie Seniors, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorea","family":"Aguinaga","sequence":"additional","affiliation":[{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"3Service H\u00e9matologie Seniors, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arij","family":"Cheffai","sequence":"additional","affiliation":[{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"3Service H\u00e9matologie Seniors, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mentine","family":"Chauvel","sequence":"additional","affiliation":[{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"4Laboratoire d\u2019H\u00e9matologie, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinaldo","family":"Dal Bello","sequence":"additional","affiliation":[{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"5Service H\u00e9matologie Adulte, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Raffoux","sequence":"additional","affiliation":[{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"5Service H\u00e9matologie Adulte, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-092X","authenticated-orcid":false,"given":"Emmanuelle","family":"Clappier","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1342, Institut de Recherche Saint-Louis, Paris, France"},{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"4Laboratoire d\u2019H\u00e9matologie, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7299-4572","authenticated-orcid":false,"given":"Matthieu","family":"Duchmann","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1342, Institut de Recherche Saint-Louis, Paris, France"},{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"4Laboratoire d\u2019H\u00e9matologie, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1342, Institut de Recherche Saint-Louis, Paris, France"},{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"3Service H\u00e9matologie Seniors, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lemaire","sequence":"additional","affiliation":[{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"4Laboratoire d\u2019H\u00e9matologie, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mathis","sequence":"additional","affiliation":[{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"4Laboratoire d\u2019H\u00e9matologie, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4376-4097","authenticated-orcid":false,"given":"Marie","family":"S\u00e9bert","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1342, Institut de Recherche Saint-Louis, Paris, France"},{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"3Service H\u00e9matologie Seniors, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-8766","authenticated-orcid":false,"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1342, Institut de Recherche Saint-Louis, Paris, France"},{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"3Service H\u00e9matologie Seniors, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-6262","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Itzykson","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1342, Institut de Recherche Saint-Louis, Paris, France"},{"name":"2Leukemia Institute Paris Saint-Louis, Paris, France"},{"name":"5Service H\u00e9matologie Adulte, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"7","key":"2025072114013761000_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"2025072114013761000_bib2","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2025072114013761000_bib3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"2025072114013761000_bib4","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025072114013761000_bib5","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"2025072114013761000_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"issue":"4","key":"2025072114013761000_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-Operative Group","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol"},{"issue":"4","key":"2025072114013761000_bib8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"6","key":"2025072114013761000_bib9","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 family expression in acute myeloid leukemia stem cells predicts clinical response to azacitidine\/venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov"},{"issue":"3","key":"2025072114013761000_bib10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"issue":"11","key":"2025072114013761000_bib11","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2025072114013761000_bib12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41375-020-0932-8","article-title":"Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy","volume":"35","author":"Cerrano","year":"2021","journal-title":"Leukemia"},{"issue":"21","key":"2025072114013761000_bib13","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025072114013761000_bib14","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party","volume":"6","author":"Tettero","year":"2022","journal-title":"HemaSphere"},{"issue":"1","key":"2025072114013761000_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.20051","article-title":"Impact of preanalytical variables on granulocytic surface antigen expression: a review","volume":"65","author":"Elghetany","year":"2005","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"2025072114013761000_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.11613\/BM.2013.018","article-title":"The Chi-square test of independence","volume":"23","author":"McHugh","year":"2013","journal-title":"Biochem Med"},{"issue":"5","key":"2025072114013761000_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s11135-006-9018-6","article-title":"A caution regarding rules of thumb for variance inflation factors","volume":"41","author":"O\u2019brien","year":"2007","journal-title":"Qual Quant"},{"issue":"1","key":"2025072114013761000_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2307\/2532740","article-title":"Maximally selected rank statistics","volume":"48","author":"Lausen","year":"1992","journal-title":"Biometrics"},{"issue":"208","key":"2025072114013761000_bib19","first-page":"1","article-title":"Choice of V for V-fold cross-validation in least-squares density estimation","volume":"17","author":"Arlot","year":"2016","journal-title":"J Machine Learn Res"},{"issue":"10","key":"2025072114013761000_bib20","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"issue":"7","key":"2025072114013761000_bib21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.26190","article-title":"Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice","volume":"96","author":"Apel","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"2025072114013761000_bib22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.27231","article-title":"Clinical outcomes of hypomethylating agents plus venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: real-world data from eight US academic centers","volume":"99","author":"Abaza","year":"2024","journal-title":"Am J Hematol"},{"key":"2025072114013761000_bib23","doi-asserted-by":"crossref","first-page":"S266","DOI":"10.1016\/S2152-2650(23)00990-4","article-title":"AML-095 findings from an analysis of patients with monocytic and monocytic-like acute myeloid leukemia (AML), including AML-M4 and AML-M5, treated with venetoclax (Ven) plus azacitidine (Aza)","volume":"23","author":"Konopleva","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8041","key":"2025072114013761000_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"issue":"6","key":"2025072114013761000_bib25","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"issue":"1","key":"2025072114013761000_bib26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cyto.b.22217","article-title":"Prospective feasibility of a minimal BH3 profiling assay in acute myeloid leukemia","volume":"108","author":"Pacchiardi","year":"2025","journal-title":"Cytometry B Clin Cytom"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3556\/2402672\/blooda_adv-2024-015734-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3556\/2402672\/blooda_adv-2024-015734-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T18:01:45Z","timestamp":1753120905000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/14\/3556\/536810\/Prognostic-significance-of-monocytic-like"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":26,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015734","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,22]]},"published":{"date-parts":[[2025,7,11]]}}}